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Abstract: The last two decades have seen the introduction of several therapies for multiple 
sclerosis (MS). These therapies are intended to work at different levels of the disease, typically 
targeting direct symptom management, brief corticosteroid administration for acute exacerba-
tions, and the regular use of disease-modifying drugs. Nevertheless, in clinical practice, disease-
modifying drugs or immunosuppressive treatments are frequently associated with suboptimal 
response in terms of efficacy and several side effects leading to poor patient adherence, so the 
proportion of relapsing–remitting MS patients not adequately responding to disease-modifying 
therapy have been reported to range from 7% to 49%. Natalizumab and fingolimod are the 
newest US Food and Drug Administration-approved agents that have been added to the MS 
treatment armamentarium, but their use is limited by a less known safety profile and recognized 
specific risk. Thus, there is an important need for new therapeutic strategies, especially those 
that may offer greater patient satisfaction and safer risk profile in order to optimize therapeutic 
outcomes. A number of potential therapies for MS are now in late-stage development. Effective, 
safe, and well-tolerated therapies may improve compliance and empower patients with a level 
of independence not presently possible. To meet these characteristics, most of these therapies 
are oral compounds. Herein, we review the pharmacology and efficacy of dimethyl fumarate 
(BG-12) to date and its role in the evolving marketplace.
Keywords: disease-modifying drugs, nuclear factor erythroid-derived 2 (E2)-related factor, 
Nrf2, oxidative stress, neuroprotection, oral treatment
Introduction
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease of the 
central nervous system (CNS). Disease onset usually occurs in young adults, and it 
is more common in females than in males (3:1). MS affects about 2.5 million people 
worldwide, and incidence and prevalence are highly variable, depending on genetics 
and several environmental factors.1 Although having wide incidence variability, MS 
is still the commonest nontraumatic cause of neurological disability in young patients 
in Western Europe and North America.2 Most patients (80%) present with a relapsing 
and remitting (RR) course, which is characterized by recurring attacks of acute focal 
neurological deficits or exacerbations of existing deficits (relapses) followed gradu-
ally by partial or full recovery (remission).3 The combination of inflammation and 
neurodegeneration makes MS a progressive disease wherein the severity and specific 
symptoms are unpredictable and often vary from one person to another. The multifo-
cal nature of the disease manifests clinically as a range of sensorimotor, cerebellar, 
visual, sphincteric, brain stem, cognitive, and neuropsychiatric symptoms. In the 
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natural history of MS, approximately 80% of patients convert 
to the secondary progressive course after 20 years, in which 
there is acceleration of disability and accumulating irrevers-
ible neurologic deficits in the absence of clinical relapses.4 
The remaining 20% with progressive clinical deterioration 
from the onset of the disease have primary progressive MS. 
According to more recent studies, the natural history of the 
disease in patients that have been treated with immunological 
agents is significantly changed, showing a more favorable 
prognosis.5,6
The exact cause of MS is still unknown, but break-
down of the blood–brain barrier (BBB) is a requirement 
for immune system access to the CNS, infiltration of the 
inflammatory cells into the CNS, and subsequent autoim-
mune demyelination. Pathological studies have shown that 
inflammatory cells not only lead to demyelination, but may 
also be involved in axon injury.7,8 MS and its animal model 
experimental autoimmune encephalomyelitis (EAE) have 
long been regarded as primarily T-helper (Th) cell type 1-me-
diated diseases; however, recent evidence suggests that Th17 
cells, a mostly unexplored subset of Th cells, may be even 
more pathogenic than Th1 cells. In the EAE model, this cell 
type is crucial for the recruitment of leukocytes into the CNS 
and for triggering parenchymal inflammation. In humans, 
Th17 cells are found in acutely active and on the borders of 
chronically active lesions. Overall, CD4+ T-cells only recog-
nize antigens presented on major histocompatibility complex 
(MHC) class II complexes, and these are seldom found in the 
CNS. MHC class I, in contrast, can be induced on neurons 
and myelin. This also makes CD8+ T-cells promising candi-
dates as effector cell types. Indeed, CD8+ T-cells outnumber 
CD4+ T-cells in the lesions of MS patients and can induce 
axonal pathology.7 MS lesions contain many inflammatory 
components, including T-cells (CD4, CD8, and gamma delta), 
plasma cells, macrophages, antibodies, and complement 
factors. Activated T-cells cross the BBB, a process that is 
mediated by interaction of very late antigen-4 on the T-cell 
surface and vascular cell adhesion molecule-1 (VCAM-1) on 
the brain vascular endothelium; infiltrating T-cells increase 
the permeability of the BBB by matrix metalloproteinases, 
which degrade the extracellular matrix.8 Activated immune 
cells in the brain interact with their responsive antigen pre-
sented by macrophages or microglia and secrete cytokines 
and chemokines that further permeabalize the BBB and fur-
ther reinforce the immune response, thus resulting in tissue 
damage. Even macrophages, which are the predominant cell 
type along the periphery of lesions, secrete tumor necrosis 
factor alpha (TNF-α) and oxygen-free radicals, leading to 
tissue damage. B-cells can both provide signaling to T-cells 
and differentiate into plasma cells, secreting antibodies that 
can bind to their antigen and activate complement, leading to 
myelin breakdown. The oligodendrocytes are damaged by a 
combination of cytokines released during the inflammatory 
reaction and possibly by direct cellular contact. Axons may 
be damaged and transected by direct attack by inflamma-
tory cells and their cytokines, or by loss of trophic support 
or protection provided by the oligodendrocytes and myelin 
membranes, respectively.9 Noninflammatory mechanisms, 
such as mitochondrial dysfunction, may also contribute to 
neurodegeneration in MS.10 Excessive release of free radicals 
may play an important role in MS pathogenesis and promote 
transendothelial leukocyte migration, as well as contribute to 
oligodendrocyte damage and axonal degeneration.11,12 Thus, 
oxidative stress, stemming from different cell types and tar-
geting several cellular components of the CNS to a variable 
extent, is involved in this detrimental concert.
On the basis of this pathologic pathway and immune 
cascade, most research is addressed at blocking a particular 
step of the immunological cascade.
Background
The arsenal for MS therapy includes treatment of acute 
relapses with corticosteroids, symptomatic treatment with 
appropriate agents, and disease modification with immuno-
modulatory agents. Relapses of MS are commonly treated 
with high-dose intravenous methylprednisolone given over 
a period of 3–5 days. This shortens relapse duration, but 
long-term effects have been poorly investigated.13,14 The 
past 20 years have seen the introduction of mainly immu-
nomodulatory agents for MS, such as interferon (IFN)-β 
and glatiramer acetate (GA). The main therapeutic goals of 
these treatments consist of clinical relapse rate reduction, 
extension of time to next relapse, reduction of new lesions 
detectable by magnetic resonance imaging (MRI), and 
decreasing the long-term accumulation of disability. The 
US Food and Drug Administration (FDA) approved the 
first disease-modifying drug (DMD) for MS, subcutaneous 
IFN-β-1b (marketed as Betaseron® [Bayer HealthCare Phar-
maceuticals, Montville, NJ, USA] in USA and as Betaferon 
[Bayer Schering Pharma AG, Berlin-Wedding, Germany] 
in the rest of the world), for RRMS in 1993. IFN-β acts as 
an anti- inflammatory drug and has several mechanisms of 
action, including a reduction in the production of IFN-γ and 
TNF-α, inhibition of T-cell activation and clonal expansion, 
modulation of cytokine and matrix metalloproteinase pro-
duction, and inhibition of T-cell migration and entry into the 
CNS.15 Currently approved immunomodulator  treatments 
for RRMS include GA and recombinant interferons 
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(IFN-β-1a; AVONEX®; Biogen Idec Inc, Cambridge, MA, 
USA, and Rebif®; Merk Serono, Merck KGaA, Darmstadt, 
Germany [EMD Serono in the United States and Canada], 
and IFN-β-1b [Betaseron®/Extavia, Bayer HealthCare 
 Pharmaceuticals Inc., Montville, NJ USA]) that represent 
first-line therapies for MS. Mitoxantrone (Novantrone®; 
Merk Serono, Merck KGaA, Darmstadt, Germany [EMD 
Serono in the United States and Canada]), natalizumab 
(Tysabri®; Biogen Idec Inc), and fingolimod (Gilenya®; 
Novartis, Basel, Switzerland) are also available for treat-
ment of MS in many countries. The IFN products are all 
thought to have similar mechanisms of action, although they 
differ in the route of administration, time of onset of action, 
and risk of induction of neutralizing antibodies.16 In con-
trast, GA – a synthetic copolymer of glutamic acid, lysine, 
alanine, and tyrosine – is believed to activate Th2 regula-
tory cells in the periphery. These activated Th2 cells cross 
the BBB and enter the CNS, where they shift the immune 
response from proinflammatory to anti-inflammatory by 
secreting cytokines that downregulate the inflammatory 
response and inhibit proinflammatory Th1 cells.17 Mitox-
antrone is an antineoplastic agent that inhibits DNA and 
RNA synthesis of B- and T-cells. While approved for the 
treatment of RRMS and secondary progressive MS,18 it has 
only shown a clear benefit for patients still experiencing 
relapses and developing new lesions that are detectable 
using MRI. Increasing recognition of short- and long-term 
risks of cardiotoxicity, acute leukemia, and bone marrow 
suppression has limited its use.19 Natalizumab is the only 
monoclonal antibody approved for the treatment of MS. It 
works by blocking leukocyte integrin α-4 and thus limits the 
migration of lymphocytes and monocytes through the BBB 
into the CNS. Large Phase III studies have been conducted 
in RRMS, where natalizumab as monotherapy was found 
to reduce MS relapses by 68% compared to placebo,20 but 
its use is restricted by its association with the development 
of progressive multifocal leukoencephalopathy (PML). As 
a result of this circumstance, health authorities granted 
approval of natalizumab only as a treatment for patients not 
responding to first-line drugs or as a first choice in patients 
with aggressive RRMS. The risk of PML (ranging from 
1/10,000 to 1/100) increases according to the presence or 
absence of three risk factors: positive status with respect 
to anti-JC virus antibodies; prior use of immunosuppres-
sant; and increasing duration of natalizumab treatment.21 
Fingolimod is the first oral drug approved for MS. The 
results of two clinical trials led to the approval of fingolimod 
by the FDA as first-line treatment, and by the European 
Medicines Agency for highly active RRMS; however, 
safety concerns include the known pharmacodynamics 
effect of the drug on heart rate and conduction, reports of 
macular edema in the fingolimod transplant program and 
in treated MS patients, and seven cases of melanoma and 
squamous cell and basal cell carcinomas.22,23 Moreover, 
there were increased risks of infection, including two 
deaths from herpes virus infections in the original Phase 
III trial, with one case of herpes virus encephalitis and one 
case of primary disseminated varicella zoster.23 All these 
mentioned warnings occurring with fingolimod treatment 
require monitoring.
Nevertheless, in clinical practice, DMDs are frequently 
associated with suboptimal response in terms of efficacy 
and several side effects leading to poor patient adherence, 
so the proportion of RRMS patients not adequately respond-
ing to disease-modifying therapy has been reported to range 
from 7%–49%, depending on the criteria used.24 Despite the 
positive therapeutic effects observed in clinical trials, many 
patients with RRMS continue to exhibit disease activity in 
daily clinical practice: 20%–50% of patients who receive 
DMD agents experience a marked increase in disability 
or a high number of relapses within a short period of time 
(,6 years) after the onset of treatment.24 Moreover, there is 
a lack of an effective treatment option for the progressive 
phase of the disease.
On the other hand, second-line treatment use is often 
limited by safety concerns, as already mentioned. Therefore, 
it is clear that there are some issues related to the treatment of 
MS patients that must be addressed. MS treatment priorities 
should be based on a better understanding of MS pathogen-
esis and heterogeneity to guide development of better thera-
pies and monitoring methods; additional treatment options 
for RRMS that are more effective, more convenient, and/or 
better tolerated, as well as some that include neuroprotective 
and repair properties, are emerging.
Several oral therapies have been evaluated in clinical tri-
als, and results presented following completion of Phase III 
trials. Fingolimod, teriflunomide, laquinimod, and dimethyl 
fumarate (DMF) results are briefly summarized in Table 1. 
The latest BG-12, will be thoroughly reviewed here, start-
ing from its mechanism of action to its possible role in MS 
treatment strategies.
Introduction to the compound
Fumaric acid esters (FAEs) are a group of similarly structured 
compounds that have been used in the treatment of psoriasis 
since 1958, originally proposed by the German biochemist 
Schweckendiek,25 who was afflicted by the disease himself. 
FAEs have been used off-label for treatment of psoriasis 
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in Europe for some time before a mixture of compounds 
consisting of DMF and three salts of ethyl hydrogen fumarate 
were licensed in Germany in 1994 as oral therapy for severe 
psoriasis under the brand name Fumaderm® (Biogen-Idec, 
Weston, MA, USA) (Figure 1).
Fumaderm® is approved as second-line therapy for severe 
systemic psoriasis in Germany but not in the USA.26 Today, 
the overall treatment experience comprises more than 180,000 
patient years and suggests a beneficial side effect profile. 
Over the past 15 years, there have been many clinical trials 
that demonstrated the immunomodulatory efficacy and safety 
profile of oral FAEs in systemic psoriasis.27
Based on similarities in the inflammatory cascade of pso-
riasis and MS, researchers hypothesized that FAEs may also 
have beneficial effects in CNS autoimmune disease, where 
MS represents the prototypic inflammatory autoimmune 
disorder of this system. This hypothesis became stronger 
with the accidental observation of MS symptom relief and 
disease stabilization in patients treated with oral fumarate 
for concomitant psoriasis.
Pharmacological properties  
and mechanism of action of FAEs
After oral intake, DMF, the main component of  Fumaderm®, is 
rapidly hydrolyzed by esterases to its metabolite  monomethyl 
fumarate (MMF). Ingestion of DMF is  associated with lower 
gastrointestinal side effects compared with MMF. After 
complete absorption in the small intestine,28 it can interact 
with immune cells in the blood circulation.29 Absorption of 
MMF is decreased by concurrent ingestion of food, though 
it remains highly bioavailable.29 MMF is the most bioactive 
Table 1 Summary of oral drugs for the treatment of relapsing-remitting multiple sclerosis
Therapy Pivotal trials Principal proposed  
mechanism of action
Administration Common adverse  
events
Serious adverse events
Fingolimod TRANSFORMS23 
FReeDOMS22
Decreased expression  
of S1p1 on lymphocytes,  
resulting in sequestration  
of lymphocytes  
in lymphoid tissue.
0.5 mg oral tablet  
taken daily
Nasopharyngitis;  
headache; fatigue;  
lymphopenia; nausea;  
increased liver enzymes;  
back pain; diarrhea.
Disseminated varicella 
zoster; herpes simplex 
encephalitis; bradycardia; 
cardiac arrhythmias; 
bronchoconstriction; macular 
edema; skin neoplasms.
Teriflunomide TeMSO55 
TeNeRe56
inhibition of pyrimidine  
biosynthesis in rapidly  
dividing cells.
14 mg oral tablet  
taken daily
Nasopharyngitis;  
gastrointestinal  
disturbance; back  
pain; elevated alanine  
aminotransferase;  
headache; fatigue; limb pain;  
urinary tract infection.
Hepatotoxicity; neutropenia; 
rhabdomyolysis; trigeminal 
neuralgia; neoplasm  
(solid tumors).
Dimethyl  
fumarate  
(BG-12)
DeFiNe45 
CONFiRM46
Decreases  
proinflammatory  
cytokines; decreases  
entrance of lymphocytes  
into CNS by decreased  
expression of adhesion  
molecules.
240 mg oral  
tablet taken  
either twice  
or thrice daily
Episodic flushing;  
gastrointestinal  
disturbance; headache;  
nasopharyngitis; fatigue.
Serious infection; 
gastroenteritis; neoplasm 
(solid tumor); gastritis.
Laquinimod* ALLeGRO57 
BRAvO58
Unknown in eAe;  
decreases entrance of  
lymphocytes into CNS;  
axon protection; decreases  
proinflammatory  
cytokines; increases levels  
of brain neurotrophic  
growth factor.
0.6 mg oral tablet  
taken daily
Chest pain; arthralgia; viral  
infection.
Hepatotoxicity; abnormal 
menstrual bleeding; 
exacerbation of preexisting 
glaucoma.
Note: *Laquinimod has not yet been approved for the treatment of MS.
Abbreviations: CNS, central nervous system; eAe, experimental autoimmune encephalomyelitis; MS, multiple sclerosis
HO
OH
O
O
Figure 1 Chemical structure of dimethyl fumarate (BG-12).
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metabolite,30 and typically reaches serum peak concentra-
tions around 20 µM. MMF is eliminated mainly through 
breathing, while only small amounts of intact MMF are 
excreted through urine or feces. There is no evidence for a 
cytochrome P450-dependent metabolism in the liver,29 thus 
few drug interactions would be expected. MMF’s half-life in 
vivo is around 12 hours.
The exact mechanism of action by which DMF and its 
primary metabolite MMF exerts its effects is still unclear and 
under research. It is now accepted that it could work at differ-
ent levels, acting at different stages and modulating different 
cells involved in the immune cascade (Figure 2).
DMF seems to interfere with cellular redox system by 
modulating intracellular thiols and thereby increasing the 
level of reduced glutathione. The major involved transcription 
factor in this process is nuclear factor erythroid-derived 2 
(E2)-related factor (Nrf2), which is released from binding 
to Keap1 via the activity of fumarates. BG-12 induces the 
cleavage of Kelch-like erythroid cell-derived protein with 
cap “n” collar homology-associated protein 1 (Keap1) from 
Nrf2 in the cell cytoplasm. By cleaving this Keap1–Nrf2 
complex, Nrf2 is free to cross the nuclear membrane and 
interact with other nuclear transcription factors to upregulate 
the antioxidant response element.31 Moreover, studies in Nrf2 
knockout mice showed that most of the therapeutic ability 
of FAEs was abolished in the absence of Nrf2. Further sup-
port for these mechanisms appeared in a recently published 
study32 that better characterizes the potential neuroprotective, 
as well as cytoprotective effects, of DMF and MMF on cel-
lular resistance to oxidative damage in primary culture of 
CNS cells. DMF and MMF treatment increase the cellular 
redox  potential, glutathione as well as adenosine triphosphate 
(ATP) levels, and the mitochondrial membrane potential in a 
concentration-dependent manner. Similarly, both DMF and 
MMF improve cell viability after reactive oxygen species 
challenge. This effect is lost in cells that have eliminated 
or reduced Nrf2 levels. These data suggest that DMF and 
MMF are cytoprotective for neurons and astrocytes against 
oxidative stress-induced cellular injury and loss via upregula-
tion of an Nrf2-dependent antioxidant response.32 Nrf2 also 
contributes to the long-term effect of DMF in neuronal cells, 
which may also involve other reported mechanisms such as 
the inhibition of the nuclear translocation of nuclear factor 
kappa-light-chain-enhancer of activated B-cells (NF-κB); 
this means an inhibition of the translocation of NF-κB into 
the nucleus and a decreased expression of NF-κB-dependent 
genes that regulate the expression of a cascade of inflamma-
tory cytokines, chemokines, and adhesion molecules.33
Evidence shows that DMF can modulate different type 
of cells in the immune system. In almost all patients treated 
with Fumaderm®, a decrease of T-cells was observed.34 
 A subsequent in vitro study detected how fumarate can 
induce apoptosis in human T-cells.35 MMF can induce an 
immune deviation, with the skewing of IFN-γ inducing 
antigen-specific Th1 cells to switch to an interleukin (IL)-
4-dominated Th2 phenotype. Th2 cells are still reactive to 
•
•
Apoptosis
Th1 to Th2 shift
• Downregulation of Th1
response
• Inhibition of TNF-α,
ICAM-1, E-selectin,
VCAM-1
T-cells and
B-cells
Endothelial
cells
Dendritic
cells
Glia
• Inhibition of
  differentiation
• Inhibition of
  proinflammatory
  cytokines
Figure 2 effects of fumaric acid esters on immune and accessory cells.
Abbreviations: Th, T-helper; TNF, tumor necrosis factor; iCAM-1, intercellular adhesion molecule 1; vCAM-1, vascular cell adhesion molecule-1.
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antigen, but provide a different cytokine pattern.36 MMF 
was shown to increase the production of the Th2 cytokines 
IL-4 and IL-5 without having an effect on the production 
of the Th1 cytokines IFN-γ and IL-2, or the proliferation of 
T-cells.36 In another study, MMF-treated monocyte-derived 
dendritic cells downregulated Th1 cell responses by signifi-
cantly decreasing the production of IFN-γ after stimulation 
by lipopolysaccharide.37
In an experiment with umbilical vein endothelial cell 
cultures, DMF inhibited the TNF-α-induced expression of 
intercellular adhesion molecule-1, E-selectin, and VCAM-1, 
impairing the migration of immune cells inside tissues.38,39 
This may correlate with the described activity of FAEs on 
NF-κB. Another consequence of the decreased expression of 
NF-κB can be speculated as an effect on B-cells. Although 
there have not been any studies on direct FAE effects on 
B-cells, there is evidence that the downregulation of NF-κB 
in turn inhibits the antiapoptotic protein Bcl-2, thus leading 
to apoptosis in B-cells.40
Efficacy of oral fumarate  
and clinical trials
Given the immunomodulatory properties of FAEs, it was sug-
gested that they could be also a beneficial effect in MS. Thus, 
the effects of FAEs in myelin oligodendrocyte glycoprotein-
induced EAE was investigated.41 Both esters had a significant 
therapeutic effect on the disease course, and histology showed 
a strongly reduced macrophage inflammation in the spinal 
cord. Cytokine analysis detected an increase of IL-10 in the 
treated animals.
Phase ii studies
An open-label, exploratory, prospective study in ten subjects 
with RRMS demonstrated that FAEs produced significant 
reductions from baseline in number (P,0.05) and volume 
(P,0.01) of gadolinium-enhancing (Gd+) lesions after 
18 weeks of treatment at a target dose of 720 mg/day admin-
istered orally; this effect persisted during the second 48-week 
treatment phase at half the target dose, after a 4-week wash-
out period. Expanded Disability Status Scale (EDSS) score, 
ambulation index, and nine-hole peg test remained stable 
or slightly improved from baseline in all patients.42
A Phase II, randomized, placebo-controlled, double-blind 
study of DMF in 257 RRMS patients has been  completed.43 
All 257 patients were randomized to DMF 120, 360, 
or 720 mg/day for 6 months. There was a subsequent 6-month 
safety extension study, in which the placebo group received the 
highest dose of 720 mg/day. When treated with 240 mg DMF 
three times daily, a 69% reduction in the mean cumulative 
number of new Gd+ lesions was observed when compared 
with placebo (P=0.002). Treated subjects also demonstrated 
advantages versus placebo in other MRI parameters: a 48% 
reduction in the mean number of new or newly enlarging 
T2-hyperintense lesions (P,0.001) and a 53% reduction in 
the mean number of new T1-hypointense lesions (P=0.014). 
Although the study was not powered to evaluate the effects 
of DMF on clinical measures, clinical efficacy end points of 
the intent-to-treat population were evaluated as exploratory 
measures. There was a 32% reduction in annualized relapse 
rate (ARR) and a 24% reduction in the proportion of relapsing 
subjects in the group treated with a high dose (240 mg three 
times daily), which was not statistically significant when com-
pared with placebo. A retrospective analysis44 of the BG-12 
Phase II trial44 was performed to evaluate the evolution of the 
new Gd+ lesions, developed between weeks 4 and 12, into 
T1 black holes. The odds ratio (OR) for this MRI parameter 
in the 720 mg/day BG-12 group compared with placebo was 
0.51 (P,0.0001). The treatment effect was greater for smaller 
lesions (OR 0.30) than for large lesions (OR 0.62).43 Analysis 
of the lower dose was not reported since it did not show a 
significant reduction in enhancing lesions.
Phase iii studies
The efficacy and safety of oral BG-12 have been further 
evaluated in two large Phase III studies (DEFINE and 
CONFIRM).45,46 Both studies were designed to investigate 
the clinical efficacy and risk–benefit profile of BG-12, were 
scheduled for 24 months, and enrolled in each case over 
1,200 adults with RRMS.
The DEFINE study was a three-arm trial over 96 weeks 
evaluating BG-12 in two dosages against placebo.45 Patients 
were randomly assigned to receive oral BG-12 at a dose of 
240 mg twice daily, BG-12 at a dose of 240 mg three times 
daily, or placebo. The primary end point was the proportion 
of patients who had a relapse by 2 years. Other end points 
included the ARR, the time to confirmed progression of 
disability defined as an increase in EDSS score of 1.0 point 
from baseline and sustained for 12 weeks, and findings on 
MRI, such as the number of Gd+ lesions and the number of 
new or enlarging T2 lesions.45 A total of 1,237 patients were 
randomly assigned to a treatment or placebo group, and 
952 patients completed the study.45 The estimated propor-
tion of patients who had a relapse was significantly lower 
in the two BG-12 groups than in the placebo group (27% 
with BG-12 twice daily and 26% with BG-12 thrice daily 
versus 46% with placebo; P,0.001 for both comparisons). 
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The annualized relapse rate at 2 years was 0.17 in the twice-
daily BG-12 group and 0.19 in the thrice-daily BG-12 group, 
as compared with 0.36 in the placebo group, representing 
relative reductions of 53% and 48% with the two BG-12 
regimens, respectively (P,0.001 for the comparison of each 
BG-12 regimen with placebo).45 The estimated proportion of 
patients with confirmed progression of disability was 16% in 
the twice-daily BG-12 group, 18% in the thrice-daily BG-12 
group, and 27% in the placebo group, with significant relative 
risk reductions of 38% with BG-12 twice daily (P=0.005) 
and 34% with BG-12 thrice daily (P=0.01). BG-12 also sig-
nificantly reduced the number of Gd+ lesions and of new or 
enlarging T2-weighted hyperintense lesions (P,0.001 for the 
comparison of each BG-12 regimen with placebo).45
The CONFIRM study had a similar trial design to DEFINE, 
with an additional, open fourth arm rater-blinded, and aimed 
to compare daily subcutaneous injections of 20 mg GA, or 
BG-12 at the dosage of 240 mg two or three times daily and 
placebo.46 The primary end point was the ARR at 2 years. 
Secondary end points were the proportion of patients with 
a relapse within 2 years, disability progression, the number 
of new or enlarging hyperintense T2 lesions, and other MRI 
parameters.46 BG-12 and GA were not directly compared in 
the CONFIRM trial, as the study was not powered to make 
such a comparison. In this study, a total of 1,430 patients were 
randomly assigned to receive treatment or placebo, and 1,417 
were included in the intent-to-treat population.46 The ARR at 
2 years was 0.40, 0.22, 0.20, and 0.29 for placebo, BG-12 twice 
daily, BG-12 thrice daily, and GA, respectively, translating into 
ARR reductions relative to placebo of 44%, 51%, and 29% for 
480 mg BG-12, 720 mg BG-12, or GA, respectively (P,0.001 
for both BG-12 dosages, P=0.01 for GA differences between 
drugs nonsignificant). Interestingly, the reduction of disease 
progression was not significant for BG-12 or GA; however, 
as compared with placebo, twice-daily BG-12, thrice-daily 
BG-12, and GA significantly reduced the numbers of new or 
enlarging T2-weighted hyperintense lesions (all P,0.001) and 
new T1-weighted hypointense lesions (P,0.001, P,0.001, 
and P=0.002, respectively).46 In post hoc comparisons of 
BG-12 versus GA, differences were not significant except for 
the annualized relapse rate (thrice-daily BG-12), new or enlarg-
ing T2-weighted hyperintense lesions (both BG-12 doses), and 
new T1-weighted hypointense lesions (thrice-daily BG-12) 
(nominal P,0.05 for each comparison).46
Safety and tolerability
The safety and tolerability of FAEs has been well known on 
the basis of the acquired experience using Fumaderm® in 
psoriasis patients. With FAE treatment of psoriasis, cases of 
acute renal failure have been reported, though other literature 
seems to refute this risk.26 No serious infections or neoplasm 
have occurred with any frequency with FAE treatment. 
Evidence-based guidelines47 for the treatment of psoriasis 
report very good long-term safety with FAEs, with more 
than 50,000 patient-years on file. In a retrospective safety 
study in patients treated with FAEs for severe psoriasis for 
up to 14 years, the most frequently reported adverse events 
(AEs) were flushing, diarrhea, and nausea. Excluding these, 
clinically relevant AEs included gastrointestinal complaints, 
flushing, lymphopenia, and eosinophilia.47
On the basis of such evidence, a new oral formulation of 
BG-12 was developed to address the gastrointestinal com-
plaints seen with FAE treatment in psoriasis. In Phase II and 
III clinical trials,43,45,46 FAEs were well tolerated, especially 
after using BG-12 containing only DMF in enteric-coated 
microtablets to improve gastrointestinal tolerability.
In a Phase IIb study in patients with RRMS, the most 
commonly reported AEs besides MS relapses were flushing 
and headache.43 Generally, flushing with BG-12 started within 
30 minutes of drug administration, subsided within 90  minutes, 
and did not lead to discontinuation.  Gastrointestinal events 
were more commonly seen with BG-12 than with placebo 
(30%–41% with BG-12 versus 25% with placebo); however, 
these were mainly mild to moderate and were reported mostly 
in the early administration of treatment.43 While no head-to-
head studies have been conducted, these events also appeared 
to occur less frequently and with a lower severity than seen 
with FAEs in psoriasis treatment, although it is not known if 
these observed reductions were due to the oral formulation 
of BG-12 or differences in the patient population. Infections 
were reported in similar proportions of BG-12 and placebo 
patients (34% in both groups).43
In Phase III studies, the overall incidence of AEs was 
similar across all treatment groups, highlighting the favor-
able safety profile of BG-12.45,46 AEs that occurred more 
frequently in patients receiving BG-12 than in patients 
receiving placebo included flushing, gastrointestinal events 
(eg, diarrhea, nausea, upper abdominal pain, abdominal pain, 
and vomiting), proteinuria, and pruritus.45,46 The incidences of 
flushing and gastrointestinal events were highest in the first 
month of the study and decreased thereafter. Overall, the inci-
dence of AEs leading to discontinuation of the study drug was 
similar across the groups in both studies, although discon-
tinuations due to flushing and overall gastrointestinal events 
occurred more frequently in patients who received BG-12 
than in patients who received placebo.45,46 The incidence 
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of infections was similar across the study groups with the 
most common infections detected being nasopharyngitis, 
upper respiratory tract infection, urinary tract infection, and 
influenza. No opportunistic infections were observed in the 
BG-12 groups, and no serious infections were reported in 
patients with lymphocyte counts of less than 0.5 × 109 per 
liter.45,46 There were no cases of malignancies associated with 
the study drug. The incidence of serious adverse events was 
similar across the study groups and there were no cases of 
renal failure classified by the investigator as serious AEs.45,46 
As expected, the mean white cell count and lymphocyte count 
decreased in patients treated with BG-12. Usually, the mean 
white cell count and lymphocyte count decreased over the 
first 12 months and then plateaued, remaining within normal 
range. Overwhelming decreases of the white cell count and 
lymphocyte count (3.0 × 109/L and 0.5 × 109/L, respec-
tively) occurred in 4%–10% of patients treated with BG-12. 
Decreases of the mean white cell count and lymphocyte 
count were not associated with an increase of infections.45,46 
In both trials, researchers observed an increased incidence of 
elevations in liver aminotransferase levels, primarily between 
months 1 and 6. No such elevations of aminotransferase levels 
were concurrent with increases in bilirubin that were more 
than two times the upper limit of the normal range. There 
were no reports of hepatic failure.45,46
Recently, four cases of PML treated with Fumaderm® 
or self-compounded DMF for psoriasis have emerged.48,49 
Only two cases48,49 may be classified as directly related to 
 fumarates. In these cases, there was a clear violation of pre-
scription information for patients with a severely reduced 
lymphocyte count or severely impaired immune system.50 
Regarding the other two cases,51 one of the patients had a 
history of treatment with efalizumab, a monoclonal anti-
body against lymphocyte function-associated antigen 1 that 
has been withdrawn from the market because of the risk of 
developing PML,51 and the other patient had neurosarcoido-
sis, which primarily predisposes to PML.
The safety and tolerability of BG-12 has been studied within 
the clinical setting for up to 2 years, in randomized controlled 
studies, and will be further studied in the 5-year extension study 
of the ENDORSE Phase III clinical trials.52
During the ENDORSE phase extension, an interim safety 
result reported 14 malignancies (13 patients), diverse in type/
location: six in patients who continued on DMF and eight 
in patients who switched to DMF. There were three deaths, 
none considered to be related to the study drug.52
Regarding pregnancy issues, the FDA classification for 
dimethyl fumarate is “pregnancy category C”.53
Future perspectives
On the basis of the results of the CONFIRM and DEFINE 
Phase III studies, the sponsors submitted regulatory approval 
to the FDA and European Medicines Agency in 2012. In 
March 2013, the FDA gave its approval to use of DMF as 
first-line therapy in patients affected by RRMS.53 Further, the 
Committee for Medicinal Products for Human Use adopted a 
positive opinion, recommending the granting of a marketing 
authorization for the medicinal drug, intended for the treat-
ment of adult patients with RRMS.54
Further information on long-term safety and efficacy of 
DMF treatment, including its suitability for use in pregnancy, 
will be obtained via implementation of respective registries 
for pregnancy and the ENDORSE study.
Conclusion
The therapeutic pipeline for MS is enriched with novel 
agents that have the potential to provide improved efficacy 
and ease of administration for patients. The development of 
drugs with easier administration, such as oral agents, would 
further promote adherence and could increase the number 
of patients with MS in treatment, reducing discomfort and 
inconvenience and making it easier for patients to adhere to 
their treatment regimen, thus improving efficacy. In view of 
these requests, the most recent therapeutic strategies have 
been developed with the intent to target specific steps in the 
pathogenesis of MS. Recent understanding of the patho-
genic mechanisms underlying MS have helped to extend 
the research field to different new drugs suitable for treating 
MS. Among these new treatment options, BG-12 seems to 
be at least equally effective as, if not more effective than, 
established injectable therapies. Moreover, the ability of 
DMF to activate Nrf2 underpins the cytoprotective modal-
ity that further augments the natural antioxidant responses 
in MS tissues. The neuroprotective effect of Nrf2 is not yet 
targeted by other MS therapies and renders the compound a 
candidate for the treatment of progressive forms of MS. In 
addition to trials on secondary or primary progressive MS 
forms, the substance may also be an effective option for the 
treatment of neurodegenerative disease.
The most challenging aspect for physicians will be mak-
ing their patients understand the need to balance the pros 
and cons of new oral treatments, where serious side effects 
may outweigh benefits in certain individuals. With gold 
standard agents such as IFN and GA, the main complaints 
are injection-site reactions and flu-like symptoms; compared 
with the higher stakes of new agents, these side effects seem 
to be more acceptable. Safety is likely to become the most 
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important factor in prescribing MS drugs in future clinical 
practice, while certainly more research is also needed to 
compare escalation, different treatment combinations, and 
induction treatment strategies.
The safety profile of BG-12 is well known from its use in 
thousands of patients with psoriasis, and undoubtedly quali-
fies the drug for long-term use. Tolerability could, however, 
become an issue, as about 15% of patients initially experi-
ence diarrhea and up to 30% experience flushing. For this 
reason, a Phase IV postmarketing study is focusing purely 
on tolerability, with the primary objective of evaluating the 
effect of symptomatic therapies on gastrointestinal-related 
events reported by patients with relapsing forms of MS by 
initiating therapy with DMF in the clinical practice setting. 
Patients will have to be educated about AEs and be closely 
supported to avoid early discontinuation of treatment. BG-12 
looks set to be very successful, as it combines a degree of 
clinical efficacy at least equal to, and probably higher than, 
established injectable therapies, with an excellent long-term 
safety profile.
The four PML cases recently reported, highlight the 
importance of close monitoring when patients undergo a new 
compound. More frequent complete blood count analyses 
may be advisable, especially after the onset of therapy, and 
an accurate evaluation of patients eligible to receive the drug. 
Similar to treatment with natalizumab, prior treatment with 
other immunosuppressants may have increased one of the 
patient’s risk of PML.
Depending on the exact licensing and on acceptance by 
both patients and neurologists, clinical routine will eventu-
ally determine where DMF treatment will be positioned 
in terms of MS therapy. On the basis of all available data, 
a widespread first-line use in treatment-naïve MS patients can 
be expected. In summary, it is anticipated that DMF will soon 
become an integral part of MS immunotherapy.
The choice between these new therapies will most likely 
be based on an overall assessment of efficacy, safety, toler-
ability, and adherence over the postmarketing period.
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